Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Shaji Kumar, ASCO 2018 – Advances in treatment approaches and guidelines for multiple myeloma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 11th 2018

We catch up with our US Editor-in-Chief to discuss advances in molecular targets and treatment in multiple myeloma, as well as important updates in the latest NCCN guidelines.

1. What do you consider the most important unmet needs in the treatment of multiple myeloma? (0:11)

2. What are the most important emerging molecular targets in the treatment of multiple myeloma? (1:14)

3. What new treatment approaches do you expect to emerge in coming years? (3:51)

4. What therapies have become available for patients with relapsed/refractory disease? (4:32)

5. What are the most important updates and changes in the latest NCCN Guidelines for multiple myeloma? (5:33)

Speaker disclosures: Shaji Kumar has nothing to disclose in relation to this video interview.

Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup